EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β ‐Lactamase Inhibitors

Ahmed M Soliman iD, Heba Abdelrasheed Allam iD, Walaa R Mahmoud iD, Bassem H Naguib iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70374 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2026. Written by Ahmed M Soliman and 3 co-authors. Institution: Pharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Shorouk, Egypt. Major MEDLINE topics: Anti-Bacterial Agents, beta-Lactamase Inhibitors, Pyrimidinones, Drug Design. 48 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A series of new substituted 1,6‐dihydropyrimidinones was designed, synthesized, and biologically evaluated as potential antibacterial candidates and β ‐lactamase enzyme inhibitors. All the synthesized compounds were tested for their antibacterial activity against Staphylococcus aureus, Bacillus subtilis as a gram‐positive species whereas Pseudomonas aeruginosa as a gram‐negative species was utilized. Most of the compounds exhibited moderate antibacterial activity compared to the reference drug amoxicillin. Furthermore, clinical antibacterial tests were conducted on β ‐lactamase resistant strains, including Acinetobacter baumannii, Bacillus subtilis , and Staphylococcus aureus . Results indicated that the candidate compounds possess potentiation effect, indicating their role as effective β ‐lactamase enzyme inhibitors. Whereas in‐vitro assay performed on β ‐lactamase enzymes revealed that compounds 3d , 3i , and 7b (IC 50 = 0.758, 0.400, and 0.524 nM) have lower IC 50 values compared to clavulanic acid (IC 50 = 0.934 nM). These findings suggested that compounds 3d , 3i , and 7b are considered as promising hits for further exploration of potent and selective β ‐lactamase inhibitors.

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial Agentsbeta-Lactamase InhibitorsPyrimidinonesDrug DesignMicrobial Sensitivity TestsStructure-Activity Relationshipbeta-LactamasesStaphylococcus aureusPseudomonas aeruginosaBacillus subtilisAcinetobacter baumannii

Author keywords

antimicrobial assaydihydropyrimidinonesβ‐lactamase inhibitor antibacterial agents

Substances

Anti-Bacterial Agentsbeta-Lactamase InhibitorsPyrimidinonesbeta-Lactamases

Authors and institutions

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Shorouk, Egypt.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

ORCID profiles: Ahmed M Soliman, Heba Abdelrasheed Allam, Walaa R Mahmoud, Bassem H Naguib

Cite

APA

Soliman, A. M., Allam, H. A., Mahmoud, W. R., & Naguib, B. H. (2026). Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β ‐Lactamase Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70374

Vancouver

Soliman AM, Allam HA, Mahmoud WR, Naguib BH. Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β ‐Lactamase Inhibitors. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70374

BibTeX
@article{Soliman2026,
  author = {Soliman, Ahmed M and Allam, Heba Abdelrasheed and Mahmoud, Walaa R and Naguib, Bassem H},
  title = {Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β ‐Lactamase Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70374}
}
Start for free →